Navigation Links
Pinn-ACL Tibial Guide2

ProductsPinn-ACL Tibial Guide2
Company Linvatec Corporation (now ConMed)
Item Pinn-ACL Tibial Guide2
Features 
  • Feature a patented collet locking mechanism for precise, fingertip control of pin-sleeve placement.
  • The guides' pin-sleeves are graduated to precisely determine tunnel length prior to drilling.
    • Description The Pinn-ACL Guide can be used to create tibial tunnels of known lengths with a variable angle adjustment of 35 to 60 degrees with the use of a graduated pin-sleeve.
    Info Linvatec Corporation (now ConMed)
    Customer Service: (800) 237-0169
    Web site: http://www.conmed.com/linvatec.php

    Related medicine products :

    1. Pinn-ACL Femoral Guide, right
    2. Ascent Primary Knee System - Ascent/Maxim CoCr I-Beam Tibial Tray
    3. Advance Uni-Comparental Knee Components - Uni All-poly Tibial Component
    4. Advance Uni-Comparental Knee Components - Uni Metal-backed Tibial Component
    5. Advance Uni-Compartmental Knee Components - Uni Metal-backed Tibial Component
    6. BioPro Uni-compartmental Knee System - Uni-compartmental Tibial Tray
    7. Genesis II Tibial Instrumentation
    8. MIS Tibial Stylus
    9. MIS Tibial Saw Guide
    10. Tibial Alignment Guide Assembly
    11. MIS Proximal Tibial Alignment Guide
    ...onal reference laboratory and a worldwide leader i...ARUP offers an extensive test menu of highly compl...ic pathology. Owned by the University of Utah, ARU...the nation's university teaching hospitals and chi...
    ...onal reference laboratory and a worldwide leader i...ARUP offers an extensive test menu of highly compl...ic pathology. Owned by the University of Utah, ARU...the nation's university teaching hospitals and chi...
    ...onal reference laboratory and a worldwide leader i...ARUP offers an extensive test menu of highly compl...ic pathology. Owned by the University of Utah, ARU...the nation's university teaching hospitals and chi...
    ...onal reference laboratory and a worldwide leader i...ARUP offers an extensive test menu of highly compl...ic pathology. Owned by the University of Utah, ARU...the nation's university teaching hospitals and chi...
    Medicine Products:
    (Date:1/8/2009)... Assembly Member Tom Torlakson Introduces AB 89 ,...wire/ -- Today, Lung Cancer Alliance-California ...rlakson (D-11th District) for his continued leader...for lung cancer research. For the third consecuti...esearch is being considered in the California Legi...
    (Date:1/8/2009)... St. Jude study could shape new treatments for sec...Newswire-USNewswire/ -- Scientists at St. Jude Chi... effective treatment for bacterial pneumonia follo...indamycin and azithromycin, which kill bacteria by...ctive than a standard first-line treatment with th...
    (Date:1/8/2009)...ick to condemn hurtful comments, study suggests ,...Many people overestimate how strongly they would r..., Sixty-three percent of study participants at Y... for an experiment with a white person rather than...ist comments about the black person when he left t...
    (Date:1/8/2009)...t St. Jude Children,s Research Hospital have demon...neumonia following influenza. They found that the ...ll bacteria by inhibiting their protein synthesis,...atment with the "beta-lactam" antibiotic ampicilli..., The finding is important because pneumonia, ra...
    Breaking Medicine News(10 mins):Health News:Lung Cancer Alliance Applauds New Legislation Funding Lung Cancer Research 2Health News:Study Finds More Effective Treatment for Pneumonia Following Influenza 2Health News:Study Finds More Effective Treatment for Pneumonia Following Influenza 3Health News:Many Turn Blind Eye to Racism 2Health News:Study finds more effective treatment for pneumonia following influenza 2Health News:Study finds more effective treatment for pneumonia following influenza 3
    .../AIDS workshop held on Tuesday speakers have raise... the disease to prevent it from spreading in the c...but a disease” was organised by the provincial AID...aboration with World Health Organisation (WHO). On...
    ...nment has said it will be increasing the salary of... and to elderly people by 10 percent from next yea... 1,400 UK community dentists. // The announcement ...eceive the same pay as their hospital counterparts...
    ...alian Institute of Health and Welfare has said tha...le diseases like HIV-AIDS, account for large sums ... Initiatives by Governments, aim at a healthy comm...se spending are just $68 a year on each South Aust...
    ...fect diagnosis elude a patient 37 times? In a path...eft behind two really young children, died due to ...ucial diagnosis of cancer, not once or twice, but ...from Rainham ,was being examined many times over t...
    Other Medicine News:Health News:37 times unlucky – Failure to Diagnose Cancer, Takes the Life of a 31 year old fathe 2
    (Date:1/6/2009)... CAMBRIDGE, Mass., Jan. 6 Cequent ...ovel products to deliver RNAi-based treatments to ...e company has recently completed a successful toxi...ministered tk RNAi therapeutic targeting the prim...al adenomatous polyposis). FAP is an inherited gas...
    (Date:1/6/2009)... PARIS, France, January 6 /PRNewswire-FirstCal... Extend the Collaboration Until,December 2011 ,...n to Include Antibody,Discovery in Ophthalmology ...o ExonHit if Allergan,Sublicenses to a Third Part...T) today announced a reinforcement,of its existin...
    (Date:1/5/2009)... BETHESDA, Md., Jan. 5 /PRNewswire-FirstCall/ ...eutical company developing novel, proprietary,ant...and autoimmune diseases,provides an outlook on k... Micromet intends to provide an update on its res...vents: , -- April 12 to 16, 2009: Update on...
    (Date:1/3/2009)... , , , , ROSEMONT, Ill., Jan. ...aging (MRI) is a growing technology providing an i... the evaluation of back pain according to an artic... American Academy of Orthopaedic Surgeons ( http:/...next several years, additional technical developme...
    Breaking Medicine Technology:Cequent to Present First Proof of Activity of an Oral RNAi Drug in Non-Human Primates at February Keystone Conference 2Cequent to Present First Proof of Activity of an Oral RNAi Drug in Non-Human Primates at February Keystone Conference 3ExonHit Therapeutics Expands Strategic Collaboration With Allergan 2ExonHit Therapeutics Expands Strategic Collaboration With Allergan 3ExonHit Therapeutics Expands Strategic Collaboration With Allergan 4Micromet Key Events for 2009 2Micromet Key Events for 2009 3Micromet Key Events for 2009 4Micromet Key Events for 2009 5MRI Emerges As Vital Resource in Treatment of Back Pain 2MRI Emerges As Vital Resource in Treatment of Back Pain 3Genaera Corporation Elects Paul K Wotton to Board of Directors 6307 1Genaera Corporation Elects Paul K Wotton to Board of Directors 6307 2Genaera Corporation Elects Paul K Wotton to Board of Directors 6307 3Genaera Corporation Elects Paul K Wotton to Board of Directors 6307 4 University Health Industries Launches Natural Pet Health Care Division 22947 1 University Health Industries Launches Natural Pet Health Care Division 22947 2Cancer Survivor Physician Writes Book 3A Conquering the Game of Life 22942 1Cancer Survivor Physician Writes Book 3A Conquering the Game of Life 22942 2New York Legislators Kill Bill for Grieving Mothers Womens Rights Activist stands up for some women and not others 22937 1New York Legislators Kill Bill for Grieving Mothers Womens Rights Activist stands up for some women and not others 22937 2
    ...ilar to IV Doses in,Phase 3 CLL Trial, BERKELEY HE...--,Genta Incorporated announced the publication of...y,s lead anti-cancer drug,Genasense(R) (oblimerse... intermittent subcutaneous (SC) injection, as well...mens may,eventually reduce or eliminate the curren...
    ...6, 2007 - Savient,Pharmaceuticals, Inc. (NASDAQ: S...Phase 2 Puricase(R) (PEG-uricase) data and,quality...e,presented at the European League Against Rheumat... 13 - 16th in Barcelona, Spain.,Puricase is a PEGy...in Phase 3 development for patients with treatment...
    Other Medicine Technology:Genta Announces Results of Phase 1 Study Using Genasense,Administered by Intermittent Subcutaneous Injection 2Genta Announces Results of Phase 1 Study Using Genasense,Administered by Intermittent Subcutaneous Injection 3Genta Announces Results of Phase 1 Study Using Genasense,Administered by Intermittent Subcutaneous Injection 4Savient Pharmaceuticals Announces Acceptance of Two Gout-Related,Abstracts for Poster Presentation at the European League Against,Rheumatism (EULAR) 2007 Annual Congress 2Savient Pharmaceuticals Announces Acceptance of Two Gout-Related,Abstracts for Poster Presentation at the European League Against,Rheumatism (EULAR) 2007 Annual Congress 3Savient Pharmaceuticals Announces Acceptance of Two Gout-Related,Abstracts for Poster Presentation at the European League Against,Rheumatism (EULAR) 2007 Annual Congress 4